Last updated: July 4, 2026
Vepdegestrant is a small-molecule oral drug candidate developed by AstraZeneca for hormone-driven cancers (notably ER-positive disease). Public supplier disclosures for vesdegestrant bulk drug (API) and finished dose (DP) are not sufficiently consolidated in open sources to name specific commercial suppliers with confidence.
Who supplies vepdegestrant API (active pharmaceutical ingredient) for development and commercialization?
Answer (open-data): No reliable, cross-verified supplier list is available in public records at the level needed to identify specific API manufacturers for vepdegestrant.
What does the public record typically show for vepdegestrant API?
For small-molecule oncology drugs, supplier identification usually appears in:
- Regulatory submissions (CTD modules, CMC sections), often not fully public until later stages.
- Drug master files (DMFs) filed by API makers (name-level access often limited).
- Inspection databases and license/permit records (not consistently searchable by drug name in a single source).
No single public source consolidates “Vepdegestrant API supplier = X” with enough completeness to be actionable for contracting or licensing decisions.
Which companies supply vepdegestrant finished dosage forms (drug product)
Answer (open-data): No defensible public list of drug product (formulation/fill-finish) contractors for vepdegestrant is available.
Where would vepdegestrant DP suppliers show up?
DP supply is commonly traceable through:
- Clinical trial material sourcing in study documentation.
- Batch release documentation and site GMP records.
- Public labels for marketed products (not available at this level if not approved).
- Patent prosecution and CMC disclosures naming manufacturing contractors (often partial).
Open materials do not provide a complete, supplier-attribution dataset for vepdegestrant DP.
What manufacturing sites or contract development and manufacturing organizations (CDMOs) make vepdegestrant?
Answer (open-data): Specific CDMO/manufacturing-site attribution for vepdegestrant cannot be stated from verified public sources.
How CDMO attribution is usually confirmed
When attribution is real, it is typically backed by at least one of:
- Named manufacturing/development contractors in regulatory CMC summaries
- Confirmed GMP site identifiers linked to batch release
- DMF-to-product crosslinks in later-stage submissions
Those linkages are not available in a consolidated, reliably named form for vepdegestrant in open literature.
Are there multiple suppliers for vepdegestrant (API and DP) or only one?
Answer (open-data): No confirmed supplier multiplicity can be stated from public sources.
What usually drives multi-sourcing
Even in early commercialization, companies often qualify:
- More than one API route (or more than one supplier for the same route)
- More than one DP site for scalability or regional supply
But vepdegestrant’s supplier network is not publicly mapped in a way that supports a decision-grade answer.
Which suppliers are likely involved based on AstraZeneca’s typical supply chain?
Answer (open-data): A likely-supplier list cannot be produced without turning speculation into facts, which would not meet the bar for business-critical supplier identification.
How to identify the real vepdegestrant supplier list using hard public hooks (Orange Book, labels, patents, filings)
Answer (open-data): No Orange Book listing exists for vepdegestrant because it is not a listed FDA-approved reference product in the Orange Book sense. Label-level supplier names are not available in a marketing label format.
Hard hooks that usually work for supplier identification
- FDA CMC listing or NDC label (not available in Orange Book format for unapproved drugs)
- Public patent filings that disclose manufacturing by named contract sites (often incomplete)
- International regulatory assessment documents where annexes identify suppliers (not consistently published for vepdegestrant)
Key Takeaways
- No validated public supplier list for vepdegestrant API or vepdegestrant drug product can be stated from consolidated open sources.
- Supplier identification at the granularity needed for contracting, licensing, or litigation support is not available in a way that can be used as “hard data” today.
FAQs
1) Is vepdegestrant currently manufactured by a CDMO that is publicly named?
No verified public source provides a defensible CDMO name-to-drug mapping for vepdegestrant.
2) Can I find the vepdegestrant API supplier via FDA Orange Book?
Orange Book supplier-level mapping is not available for unapproved drugs in that format.
3) Do vepdegestrant patents list the API or DP manufacturing contractor?
Patents may reference synthesis and intermediates, but they do not reliably disclose the specific commercial supplier for API/DP.
4) Are there multiple API suppliers for vepdegestrant?
Open sources do not provide a confirmed multi-sourcing picture.
5) Where do supplier names usually appear for small-molecule oncology drugs?
In later-stage regulatory submissions, DMF crosslinks, GMP site references, and marketed label documentation.
References
- AstraZeneca product and pipeline materials (public sources accessed via company website and press releases for vepdegestrant background).
- FDA Orange Book: Drug Products Listed in the Orange Book (for supplier-level label linking where applicable).
